Illumina is trading 4.6% up at $217.78, supported by continued momentum ahead of its S&P 500 inclusion, effective before the September 21, 2026 open.

  • UBS upgraded Illumina to Buy on September 9 and set a $260 price target.
  • No new major company announcement was identified on September 15.
  • The move is notable as biotech and major indexes are lower.